Lipella Pharmaceuticals
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Lipella Pharmaceuticals was a Pittsburgh-based clinical-stage biotech company that developed drugs by reformulating the active agents in existing generic drugs. Its lead candidate, LP-10, was a liposomal oral rinse of the immunosuppressant tacrolimus for symptomatic oral lichen planus (OLP), a chronic inflammatory mouth condition — with the goal of becoming the first FDA-approved OLP treatment. Other programs included LP-310 (tacrolimus for oral lichen planus), LP-410 (oral liposomal tacrolimus for graft-versus-host disease) and LP-50 (intravesical immunoglobulins for bladder cancer).
02 / Lipella Pharmaceuticals FAILURE REASONS
Why it failed
Lipella ran out of money before it could turn promising data into an approvable product. In September 2025, LP-10 hit the key safety endpoint in a 27-patient phase 2a study with meaningful reductions in pain and sensitivity, and the company planned a phase 2b. But it was delisted from Nasdaq after its stock was suspended on June 20, 2025, cutting off its funding lifeline. With no path to finance the next trial, the company filed a voluntary Chapter 11 petition on March 30, 2026 to pursue an asset sale 'to maximize value for creditors.'
03 / EVENT HISTORY
Events in the structured record
- Recorded founding
The dataset records founding in 2017; securities profiles list incorporation in Pittsburgh in 2005 — a discrepancy noted here.
- Nasdaq delisting
After LP-10's positive phase 2a readout in September 2025, Nasdaq suspended Lipella's stock on June 20, 2025 and announced its delisting; trading moved to the OTC market.
- Chapter 11 and asset sale
On March 30, 2026 Lipella filed a voluntary Chapter 11 petition in the U.S. Bankruptcy Court for the Western District of Pennsylvania (Case No. 26-20879-CMB). On May 14, 2026 it signed an Asset Purchase Agreement with XRAIY for substantially all assets, approved by the court on June 4, 2026 under section 363 of the Bankruptcy Code.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Nasdaq suspended trading of Lipella's common stock on June 20, 2025, delisting the company.
- 02
On March 30, 2026, Lipella filed a voluntary Chapter 11 petition in the Western District of Pennsylvania to run an asset sale process maximizing value for creditors.
- 03
An Asset Purchase Agreement with XRAIY was signed on May 14, 2026 and approved by the court on June 4, 2026 under section 363.